Determination of Regulatory Review Period for Purposes of Patent Extension; DOPTELET

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for DOPTELET, a human drug product, and published the notice as required by law. The FDA made this determination due to a patent extension application submitted to the US Patent and Trademark Office (USPTO) at the Department of Commerce.